Clinical trial
PPIO-009 Tumor Regression Grade and Prognosis Analysis of Esophageal Cancer in Different Tumor Location After Neoadjuvant Immunotherapy
NCT06453395 is registered in ClinicalTrials.gov with Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PPIO-009 Tumor Regression Grade and Prognosis Analysis of Esophageal Cancer in Different Tumor Location After Neoadjuvant Immunotherapy
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 1, 2023
- Completion date
- June 4, 2024
- Enrollment
- 248 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
tumor regression grade